View in your browser

The Digital Examiner
     www.prostaid.org    

“Issue #305” May 2025
Upcoming Events
Prostaid Calgary AGM
The must attend event of the year!
May 29 At The Grey Eagle Casino
3777 Grey Eagle Dr, Calgary
Come and join us for this great night of
Business, Food, Entertainment and Fellowship
 Our 50/50 Raffle is already over $100
Get ready to laugh with our special guest
Anne Mulders 
Watch your email for a special invitation
 
Warriors Lunch

Reminder to all our Warriors that our next pizza lunch at Bella Roma Pizza in Lakeview is scheduled for Tuesday May 6th starting at 11:30 am.

Contact Jim to confirm your attendance and don't forget to bring $20 to help cover the cost.            RSVP jim.richardson@telus.net

Bella Roma Pizza #17 6449 Crowchild Tr. SW.

                       

All of our monthly General meetings are in person or via Zoom

Location for in person is:

CKE Community Centre (1015 73 Ave SW, Calgary, AB

 If you are interested in attending via Zoom please sign up HERE

 

Warriors & Wives Partners and Caregivers

Join us on Wednesday, June 18th. We are meeting at CKE starting at 6:00 pm with a social gathering in the lounge and separate meetings from 6:30 to 7:30 prior to the general meeting in the main hall.
Exciting Opportunity Alert!  Prostaid Calgary is on the lookout for passionate individuals eager to make a real difference. Join us as a Board Member and play a vital role in our impactful mission. Your skills and dedication can help shape a brighter future.  "If you believe this is the perfect opportunity for you, we'd love to hear from you!                                                                                                                    Reach out to any of our Board members or connect with me directly at program.director@prostaid.org. 
Donate Today
Donate Today

PROSTAID Calgary is a registered charity that relies on the generosity of its members, supporters and friends to achieve its goals. Tax receipts are issued for all amounts over $20.00.                                                 
Your donations are used to support our monthly journal (the Digital Examiner), our free online video library, our website, our outreach programs and general awareness.
Donate Today
Connect With Us
Information                                                      Phone 403 455 1916                                      
info@prostaid.org                                         
Brad Sterling                                                   
President                                                          
president@prostaid.org
Connect With Us 
Support Groups
Jim Richardson                                              Warriors                                                           
jim.richardson@telus.net
Wives, Partners & Caregivers
Newly Diagnosed
info@prostaid.org
Meeting Info Here
Articles Of Interest
DRIVING CHANGE FOR MEN’S HEALTH
The MAN VAN® is Canada’s first and only mobile men’s health clinic offering FREE PSA (Prostate Specific Antigen) blood testing used for early detection of prostate cancer.
Now serving Edmonton & north for men 50 to 70 years of age
-No appointment necessary
-Testing ages 40 to 80
-Find the next community clinic near you
-15 minutes can save your life!
MAN VAN UPCOMING CLINICS

How a Minnesota medtech startup treats prostate cancer with water
Prostate removal can disrupt a man's urinary, bowel and sexual functions. Richard Hill, Francis Medical's marketing director, said the company's device seeks to aggressively treat cancer while allowing a patient to maintain quality of life.
 
More Trial Info                                            
                                                                                                April 2025                                              
MedicalXpress
Water Treatment

Genetic test can predict risk of toxicity following radiation for prostate cancer
"While tumour-based molecular profiling tests that inform treatment selection have contributed to improved patient outcomes, no tests based on germline genetics currently exist to identify toxicity risks to treatment. PROSTOX ultra is the first test that predicts radiation toxicity, giving patients and their physicians important information to make decisions that balance effectiveness with long-term quality of life.”
 
                   
April 2025                                                                      Urology Times
Prostox

Key mechanism behind prostate cancer drug resistance reveals potential new treatment strategy
Prostate cancer patients that don't respond to usual hormonal treatments are given enzalutamide, which is an androgen receptor inhibitor, also known as an antiandrogen. These medications block androgens () from binding to their receptors, which disrupts their normal behaviour and can slow down prostate cancer progression.
 
                                                                                                      March 2024                                                                        Journal of Clinical Oncology
Drug Resistance

New study shows non-attenders are at significantly greater risk of death

Comparing outcomes with a control group of men who had never been invited for screening, men who attended screening appointments had a 23% lower risk of dying from prostate cancer, while non-attenders faced a 39% higher risk of death from the disease. This indicates a great mortality benefit from prostate cancer screening than previously thought.

April 2025                                                                      Europa-Uomo
Screening

Residual Cancer After Neoadjuvant Tx Predicts High-Risk Prostate Cancer Outcomes
Residual disease burden after intensified neoadjuvant therapy (NAT) using androgen deprivation therapy (ADT) and an androgen receptor pathway inhibitor (ARPI) for high-risk prostate cancer predicts metastatic recurrence after radical prostatectomy (RP), a new study finds.
 
 
April 2025                                                      Renal+Urology
High-Risk

Dose expansion begins in phase 1/2 trial of 67Cu-SAR-bisPSMA in mCRPC

The dose expansion phase of the study is assessing outcomes with 67Cu-SAR-bisPSMA at a dose level of 8 GBq, which was selected following a recommendation from the safety review committee (SRC). The SRC also suggested that the phase 2 portion of the trial increase the number of cycles from up to 4 to up to 6.

Trial Updates

                                                                                                    April 2025                                                                      Urology Times                                                                                       
Dose Expansion

Polygenic Risk Score May Have Clinical Utility for Prostate Cancer Screening
“In a population-based prostate cancer screening program involving participants in the top decile of risk as determined by a polygenic risk score, the percentage found to have clinically significant prostate cancer […] was higher than the percentage that would have been identified with the use of PSA or MRI.”
 
 
April 2025                                                                      Renal+Urology
Risk Score

Blue Laser Vaporization Effective for Benign Prostatic Hyperplasia

Blue laser vaporization alleviates lower urinary tract symptoms while preserving sexual function in patients undergoing benign prostatic hyperplasia (BPH) surgery, according to a study published online March 4 in The Aging Male.

Study Results

April 2025                                                      Renal+Urology
Blue Laser

ClarityDX technology can be used to predict the risk of disease.

When it comes to a cancer diagnosis, Clarity means peace of mind. And when it comes to prostate cancer detection, it takes the right data to deliver that Clarity.

ClarityDX Prostate is a clinically proven decision support tool that uses a machine learning platform to calculate an accurate prostate cancer risk score from clinical data and multiple blood-based PSA test results (5-7).

If you have an elevated PSA, or a suspicion of prostate cancer, ClarityDX Prostate may be right for you. ClarityDX Prostate takes the fear and uncertainty out of prostate cancer screening.
ClarityDX

Read about these articles below

1-Reduce cancer fatigue
2-Robot-assisted HIFU for prostate cancer
3-Favourable PSA Dynamics
4-Cancer's 'fingerprints' in blood plasma
5-Managing lower urinary tract symptoms
6-New biopsy technique
7-NeuroSAFE Improves Erectile Function                                                                              8- Ultrasound could enable faster prostate cancer diagnosis                                      9-Canadian Prostate Cancer Guide                                                                                   10-3-fraction SBRT regimen                                                                                        

P.O. Box 72126
R.P.O. Glenmore Landing
Calgary, Alberta T2V 5H9
Articles For Everyone

Personalized app shown to reduce cancer-related fatigue
One of the most common side effects of cancer treatments, including chemotherapy and radiation therapy, is fatigue. Cancer-related fatigue is often worse and harder to manage compared to the fatigue in people without cancer and can sometimes persist weeks, months or even years after treatment ends.
 
                                                                                                April 2025
Biomedical Technology 
Cancer Fatigue

Urologists perform first remote robot-assisted HIFU for prostate cancer

Urologists from Cleveland Clinic have collaborated across borders to perform the world’s first remotely conducted robot-assisted high-intensity focused ultrasound (HIFU) focal therapy procedure for prostate cancer.1

Remote operation for the HIFU procedure was conducted by Ruben Olivares, MD, of Cleveland Clinic’s main campus, who was more than 7000 miles away from the procedure that was performed at Cleveland Clinic Abu Dhabi.

                                                                                                April 2025                                                                      Urology Times                                                                    
Robot-Assisted

Favourable PSA Dynamics Indicate Response to ARSI Doublet Therapy in mCSPC

ARSI doublet therapy induced deeper and faster PSA responses compared with combined androgen blockade in men with mCSPC.

Response rates to androgen receptor signaling inhibitors (ARSIs) in metastatic castration-sensitive prostate cancer (mCSPC) are higher among patients achieving an ultra-low PSA nadir, a high PSA response rate, and a longer time in PSA nadir (TTN), a new study finds.

Study Details

                                                                                                           April 2024                                                                         Renal + Urology News                                                                          
PSA Dynamics

Using pulsed infrared light to find cancer's 'fingerprints' in blood plasma

Plasma is the liquid portion of blood, depleted of any cells. It carries diverse molecules such as proteins, metabolites, lipids and salts throughout the body. Some molecules carried by blood plasma indicate potential health conditions. For example, unusually high levels of prostate-specific antigen are used to screen for prostate cancer. 

More Info Here                                                                                                                                                                           April 2025                                                                      MedicalXpress
Plasma

App shows promise in managing lower urinary tract symptoms
 

The app incorporates various modules focusing on physiotherapy, lifestyle adjustments, and other resources aimed at enhancing patient motivation and adherence. It also includes a game that can be played to defer the urge to void. The primary outcome, the International Prostate Symptom Score (IPSS), showed a significant 8-point reduction in the intervention group, whereas no change was observed in the control group.                                                                                                                                                       April 2025                                                                      Urology Times

                                                                                                     
Urinary Symptoms

More pain, more gain? New biopsy technique found to improve prostate cancer detection
Researchers and doctors have been looking for ways to improve the needle biopsy process, largely due to the concern of infections from the biopsy process. One option has been to change the route through which the needle passes into the prostate, which would be for it to go through the skin instead of the bowel lining.
 
                                                                 
March 2025                                                                    MedicalXpress
Biopsy

NeuroSAFE Improves Erectile Function, Urinary Continence in Prostate Cancer

A major challenge we face is how to cure [patients] but also ensure they can live life to the [fullest] afterwards. This study is promising and provides evidence that innovative types of surgery can reduce erectile dysfunction in some [patients]. However, more research is needed to prove whether NeuroSAFE is as effective as traditional techniques at delivering a complete cure.”

More Info Here

                                                                                                   March 2025                                                                      Cancernetwork

Erectile Function

High resolution ultrasound could enable faster prostate cancer diagnosis
MicroUS was able to identify prostate cancer as effectively as MRI-guided biopsy, with very similar rates of detection across all three arms of the trial. There was little difference even in the group who received both types of biopsies, with the microUS detecting the majority of significant cancers.
 
 
March 2025                                                               Radiology & Imaging
 
Ultrasound
Bringing you the most up to date information in treatments, support, well-being, and more all in one place
 
We can help you in achieving the support you’re looking for. On the Canadian Prostate Cancer Guide website you can look to find the most up to date information on prostate cancer in one place.
 
Learn More Here

Study underway to assess 3-fraction SBRT regimen in prostate cancer
"The goal of the PRECISION study is to ensure that treatment with 3 radiation doses does not lead to greater side effects than those observed in the PACE-B study. I am confident that we can demonstrate effective cancer treatment with less side effects."
 
 
April 2025                                                                      Urology Times
3-Fraction Regimen
Disclaimer: The PROSTAID Calgary Society website & newsletter provides news and information about prostate issues and activities of the organization. While information is presented about prostate cancer and related issues, it is not intended as a substitute for professional medical advice, diagnosis, or treatment. PROSTAID Calgary Society recommends that you seek the advice of your physician or other qualified health professionals regarding questions you may have about any medical condition. Topics on PROSTAID Calgary Society’s website & newsletter are presented to inform you and we encourage you to seek professional medical advice before starting any treatment.
P.O. Box 72126
R.P.O. Glenmore Landing
Calgary, Alberta T2V 5H9